{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T07:35:35Z","timestamp":1765438535241,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T00:00:00Z","timestamp":1542240000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Twelfth Five-Year Project on Tackling Key Problems of National Science and Technology","award":["2012ZX10001002-002-013"],"award-info":[{"award-number":["2012ZX10001002-002-013"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81171619"],"award-info":[{"award-number":["81171619"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12879-018-3489-7","type":"journal-article","created":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T12:23:35Z","timestamp":1542284615000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Research on the treatment effects and drug resistances of long-term second-line antiretroviral therapy among HIV-infected patients from Henan Province in China"],"prefix":"10.1186","volume":"18","author":[{"given":"Junli","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingquan","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,15]]},"reference":[{"issue":"9562","key":"3489_CR1","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(07)60315-8","volume":"369","author":"Z Wu","year":"2007","unstructured":"Wu Z, Sullivan SG, Wang Y, Rotheram-Borus MJ, Detels R. Evolution of China's response to HIV\/AIDS. Lancet. 2007;369(9562):679\u201390.","journal-title":"Lancet"},{"key":"3489_CR2","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/sj.cr.7290366","volume":"15","author":"J Shen","year":"2005","unstructured":"Shen J, Yu DB. Governmental policies on HIV infection in China. Cell Res. 2005;15:903\u20137. https:\/\/doi.org\/10.1038\/sj.cr.7290366 .","journal-title":"Cell Res"},{"key":"3489_CR3","unstructured":"Chinese Center of Disease and Control. Chinese National Free AIDS Antiretroviral Therapy Manual, 2007."},{"issue":"91","key":"3489_CR4","first-page":"1443","volume":"21","author":"H Li","year":"2011","unstructured":"Li H, Guo W, Li H, et al. Analysis of HIV-1 resistance in AIDS patients from a six-year cohort treated with antiviral therapy in a rural area in Henan Province. Chin J Med. 2011;21(91):1443\u20137.","journal-title":"Chin J Med"},{"issue":"1","key":"3489_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/QAI.0b013e31818ffcdc","volume":"50","author":"M Luo","year":"2009","unstructured":"Luo M, Liu H, Zhuang K, et al. Prevalence of drug-resistant HIV-1 in rural areas of Hubei Province in the People\u2019s Republic of China. Jaids-J Acq Imm Def. 2009;50(1):1\u20138.","journal-title":"Jaids-J Acq Imm Def"},{"issue":"9","key":"3489_CR6","doi-asserted-by":"crossref","first-page":"361","DOI":"10.7883\/yoken.JJID.2008.361","volume":"61","author":"M Zhang","year":"2008","unstructured":"Zhang M, Han XX, Cui WG, et al. The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation. Jpn J Infect Dis. 2008;61(9):361\u20135.","journal-title":"Jpn J Infect Dis"},{"issue":"10","key":"3489_CR7","first-page":"1101","volume":"31","author":"M Zhang","year":"2008","unstructured":"Zhang M, Han X, Hu Q, et al. Cohort study of highly active antiretroviral therapy and drug resistant mutation in Henan Province, China. Chin J Lab Med. 2008;31(10):1101\u20134.","journal-title":"Chin J Lab Med"},{"key":"3489_CR8","unstructured":"Chinese Center of Disease and Control. Epidemic situation and the main prevention and control work progress of the national AIDS STD in May 2016. Chin J AIDS STD. 2016;(7):487."},{"key":"3489_CR9","volume-title":"Short-term efficacy of second-line antiretroviral therapy for AIDS patients","author":"H Ning","year":"2009","unstructured":"Ning H, Liang H. Short-term efficacy of second-line antiretroviral therapy for AIDS patients. Shaanxi: Fourth National Conference of Chinese Medical Institute on AIDS, Viral Hepatitis C and tropical diseases; 2009."},{"issue":"6","key":"3489_CR10","first-page":"40","volume":"6","author":"QI Min","year":"2011","unstructured":"Min QI, Guo-qiang Z, Wang L-j, Ke Z, Guo-tao L. Efficacy of second-line antiviral therapy for AIDS. J Clin Appl Med. 2011;6(6):40\u20131.","journal-title":"J Clin Appl Med"},{"issue":"10","key":"3489_CR11","doi-asserted-by":"publisher","first-page":"e110259","DOI":"10.1371\/journal.pone.0110259","volume":"9","author":"M Zhang","year":"2014","unstructured":"Zhang M, Shang M, Yang W, Chen J, Wang Z, Shang H. Treatment effect and drug-resistant mutations in chinese AIDS patients switching to second-line antiretroviral therapy. PLoS One. 2014;9(10):e110259.","journal-title":"PLoS One"},{"key":"3489_CR12","first-page":"776","volume":"09","author":"H Ding","year":"2017","unstructured":"Ding H, Liu J, He Y, et al. Efficacy of long-term second-line antiretroviral therapy in HIV \/ AIDS patients in China. Chin J AIDS STD. 2017;09:776\u20139.","journal-title":"Chin J AIDS STD"},{"issue":"10","key":"3489_CR13","first-page":"711","volume":"18","author":"YM JianLiu","year":"2012","unstructured":"JianLiu YM, Zhang F. HIV antiretroviral therapy mode and the current situation in China. Chin J AIDS STD. 2012;18(10):711\u20134.","journal-title":"Chin J AIDS STD"},{"issue":"4","key":"3489_CR14","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/QAI.0b013e3181bcdac1","volume":"53","author":"MP Fox","year":"2010","unstructured":"Fox MP, Ive P, Long L, Maskew M, Sanne I. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010;53(4):500\u20136.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"8","key":"3489_CR15","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1468-1293.2010.00825.x","volume":"11","author":"MC Hosseinipour","year":"2010","unstructured":"Hosseinipour MC, Kumwenda JJ, Weigel R, et al. Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med. 2010;11(8):510\u20138. https:\/\/doi.org\/10.1111\/j.1468-1293.2010.00825.x .","journal-title":"HIV Med"},{"key":"3489_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1758-2652-14-14","volume":"14","author":"L Ferradini","year":"2011","unstructured":"Ferradini L, Ouk V, Segeral O, et al. High efficacy of lopinavir\/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER\/Calmette Hospital in Phnom Penh, Cambodia. J Int AIDS Soc. 2011;14:14.","journal-title":"J Int AIDS Soc"},{"issue":"8","key":"3489_CR17","doi-asserted-by":"publisher","first-page":"E341","DOI":"10.1016\/S2352-3018(17)30065-6","volume":"4","author":"NI Paton","year":"2017","unstructured":"Paton NI, Kityo C, Thompson J, Nankya I, Bagenda L, Hoppe A, Hakim J, Kambugu A, van Oosterhout JJ, Kiconco M, et al. Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial. Lancet HIV. 2017;4(8):E341\u20138.","journal-title":"Lancet HIV"},{"issue":"1","key":"3489_CR18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S1473-3099(17)30630-8","volume":"18","author":"JG Hakim","year":"2018","unstructured":"Hakim JG, Thompson J, Kityo C, Hoppe A, Kambugu A, van Oosterhout JJ, Lugemwa A, Siika A, Mwebaze R, Mweemba A, et al. Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial. Lancet Infect Dis. 2018;18(1):47\u201357.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"3489_CR19","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1089\/aid.2011.0352","volume":"28","author":"SJ Reynolds","year":"2012","unstructured":"Reynolds SJ, Laeyendecker O, Nakigozi G, et al. Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. AIDS Res Hum Retroviruses. 2012;28(12):1739\u201344.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"3","key":"3489_CR20","doi-asserted-by":"publisher","first-page":"e32144","DOI":"10.1371\/journal.pone.0032144","volume":"7","author":"JH Levison","year":"2012","unstructured":"Levison JH, Orrell C, Gallien S, et al. Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa. PLoS One. 2012;7(3):e32144.","journal-title":"PLoS One"},{"key":"3489_CR21","first-page":"769627","volume":"2011","author":"CL Wallis","year":"2011","unstructured":"Wallis CL, Mellors JW, Venter WD, et al. Protease inhibitor resistance is uncommon in HIV-1 subtype C infected patients on failing second-line Lopinavir\/r-containing antiretroviral therapy in South Africa. AIDS Res Treat. 2011;2011:769627.","journal-title":"AIDS Res Treat"},{"issue":"2","key":"3489_CR22","doi-asserted-by":"publisher","first-page":"E42","DOI":"10.1016\/S2352-3018(14)00061-7","volume":"2","author":"MA Boyd","year":"2015","unstructured":"Boyd MA, Moore CL, Molina J-M, Wood R, Madero JS, Wolff M, Ruxrungtham K, Losso M, Renjifo B, Teppler H, et al. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis. Lancet HIV. 2015;2(2):E42\u201351.","journal-title":"Lancet HIV"},{"issue":"8","key":"3489_CR23","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1097\/QAD.0b013e328351f5b2","volume":"26","author":"O Ajose","year":"2012","unstructured":"Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. Aids. 2012;26(8):929\u201338.","journal-title":"Aids"},{"key":"3489_CR24","unstructured":"Chinese Center of Disease and Control. Chinese National Free AIDS Antiretroviral Therapy Manual, 2009."},{"key":"3489_CR25","unstructured":"World Health Organization. Rapid advice: Antiretroviral therapy for HIV infection in adults and adolescents. 2009, ( https:\/\/www.ghdonline.org\/uploads\/Rapid_Advice_Adult_ART_Guidelines_web.pdf )."},{"key":"3489_CR26","unstructured":"Zhang M, Cui W, et al. Efficacy of anti-HIV treatment and drug-resistance mutations in some parts of China. Zhonghua Yi Xue Za Zhi. 2005;85(11):760-4."},{"issue":"2","key":"3489_CR27","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/QAI.0b013e3182615ad1","volume":"61","author":"RA Murphy","year":"2012","unstructured":"Murphy RA, Sunpath H, Castilla C, et al. Second-line antiretroviral therapy: long-term outcomes in South Africa. J Acquir Immune Defic Syndr. 2012;61(2):158\u201363.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3489_CR28","unstructured":"HIV Drug Resistance Database. https:\/\/hivdb.stanford.edu\/dr-summary\/resistance-notes\/NRTI\/"},{"issue":"6","key":"3489_CR29","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2217\/hiv.09.40","volume":"3","author":"BG Brenner","year":"2009","unstructured":"Brenner BG, Coutsinos D. The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications. HIV Ther. 2009;3(6):583\u201394.","journal-title":"HIV Ther"},{"key":"3489_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3402\/gha.v7.24861","volume":"7","author":"S Khan","year":"2014","unstructured":"Khan S, Das M, Andries A, et al. Second-line failure and first experience with third-line antiretroviral therapy in Mumbai, India. Glob Health Action. 2014;7:1\u20136.","journal-title":"Glob Health Action"},{"issue":"11","key":"3489_CR31","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/infdis\/jis261","volume":"205","author":"KCE Sigaloff","year":"2012","unstructured":"Sigaloff KCE, Hamers RL, Wallis CL, et al. Second-line antiretroviral treatment successfully Resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in sub-Saharan Africa. J Infect Dis. 2012;205(11):1739\u201344.","journal-title":"J Infect Dis"},{"issue":"6","key":"3489_CR32","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1177\/095632020701800603","volume":"18","author":"JK Ly","year":"2007","unstructured":"Ly JK, Margot NA, MacArthur HL, et al. The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65R+M184V. Antivir Chem Chemother. 2007;18(6):307\u201316.","journal-title":"Antivir Chem Chemother"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3489-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-018-3489-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3489-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T03:50:20Z","timestamp":1694058620000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-018-3489-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,15]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3489"],"URL":"https:\/\/doi.org\/10.1186\/s12879-018-3489-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2018,11,15]]},"assertion":[{"value":"14 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research was approved by the Ethics Committee of the first Affiliated Hospital of China Medical University. All participants signed informed consent statements.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"571"}}